Westfield Capital Management Co. LP Has $28.18 Million Position in Aclaris Therapeutics Inc (ACRS)

Westfield Capital Management Co. LP lessened its holdings in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 12.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,091,944 shares of the biotechnology company’s stock after selling 157,310 shares during the quarter. Westfield Capital Management Co. LP owned 3.54% of Aclaris Therapeutics worth $28,183,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of ACRS. Citigroup Inc. grew its holdings in Aclaris Therapeutics by 171.8% in the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 2,726 shares during the last quarter. UBS Group AG grew its holdings in Aclaris Therapeutics by 60.4% in the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 1,681 shares during the last quarter. Legal & General Group Plc grew its holdings in Aclaris Therapeutics by 98.3% in the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 2,605 shares during the last quarter. Bank of Montreal Can grew its holdings in Aclaris Therapeutics by 1,793.1% in the 2nd quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 6,760 shares during the last quarter. Finally, Voya Investment Management LLC bought a new stake in Aclaris Therapeutics in the 2nd quarter worth $247,000. Institutional investors own 92.10% of the company’s stock.

A number of equities research analysts have issued reports on the stock. BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Zacks Investment Research raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a report on Tuesday, October 10th. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 4th. ValuEngine lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $39.00 target price on shares of Aclaris Therapeutics in a research note on Friday, September 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $39.20.

Shares of Aclaris Therapeutics Inc (NASDAQ ACRS) opened at $21.47 on Tuesday. Aclaris Therapeutics Inc has a 52 week low of $21.32 and a 52 week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.23. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $2.00 million. equities analysts expect that Aclaris Therapeutics Inc will post -2.59 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Westfield Capital Management Co. LP Has $28.18 Million Position in Aclaris Therapeutics Inc (ACRS)” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/05/westfield-capital-management-co-lp-has-28-18-million-position-in-aclaris-therapeutics-inc-acrs.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

What are top analysts saying about Aclaris Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aclaris Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit